INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 134 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2019. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $800,311 | -15.7% | 15,364 | +2.5% | 0.00% | -25.0% |
| Q2 2023 | $949,357 | +28.7% | 14,993 | +10.0% | 0.00% | +33.3% |
| Q1 2023 | $737,794 | -6.1% | 13,625 | -8.2% | 0.00% | -25.0% |
| Q4 2022 | $785,439 | +109.5% | 14,842 | +84.3% | 0.00% | +100.0% |
| Q3 2022 | $375,000 | +29.3% | 8,054 | -11.8% | 0.00% | +100.0% |
| Q4 2020 | $290,000 | -50.1% | 9,132 | -82.1% | 0.00% | -75.0% |
| Q4 2018 | $581,000 | -62.8% | 51,030 | -29.0% | 0.00% | -50.0% |
| Q3 2018 | $1,560,000 | -11.2% | 71,905 | -27.6% | 0.01% | -20.0% |
| Q2 2018 | $1,756,000 | +132.9% | 99,370 | +63.7% | 0.01% | +100.0% |
| Q2 2017 | $754,000 | – | 60,720 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |